What You Need to KnowBackgroundWe aimed to identify biomarkers that might be used to predict response of patients with inflammatory bowel diseases (IBD) to vedolizumab therapy.FindingsIn colon tissues from patients with IBD, we identified 4 genes whose baseline expression levels were associated with remission, based on endoscopic features, after vedolizumab but not anti--tumor necrosis factor treatment. We validated this signature in 4 independent datasets and also at the protein level. Studies of these genes might provide insights into the mechanisms of action of vedolizumab.Implications for patient careAnalysis of this gene expression patterns in colon tissues of patients with IBD might be used to identify those most likely to respond to vedolizumab therapy.

The landscape of inflammatory bowel disease (IBD) treatment has extensively changed over the past decade, with the advent of anti--tumor necrosis factor (TNF) agents, antiadhesion molecules, and anti-interleukin (IL) 12/23 compounds inducing and maintaining clinical and endoscopic remission.[@bib1] Nevertheless, primary nonresponse and secondary loss of response compromise the efficacy of the current available therapies. Hence, novel therapies are eagerly awaited,[@bib2] as well as predictive biomarkers, which can improve the likelihood of successful treatment.

Biomarkers predicting response to anti-TNF therapy are slowly emerging[@bib3], [@bib4], [@bib5], [@bib6], [@bib7] but need further validation before translation into clinical practice. In contrast, vedolizumab-specific biomarkers are even more limited, with studies focusing only on prediction of clinical response.[@bib8]^,^[@bib9] As targets in IBD are evolving from clinical to endoscopic remission,[@bib10] biomarker development should focus on the prediction of endoscopic remission.

Vedolizumab, a humanized monoclonal antibody targeting the α4β7 integrin, has proven to be a safe and efficacious drug to induce and maintain clinical remission in patients with Crohn's disease (CD) and ulcerative colitis (UC).[@bib1] By disturbing the interaction between mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) on the intestinal endothelial cells and α4β7 integrin, expressed on a variety of circulating leukocytes, vedolizumab is primarily a gut-focused drug. Although it has always been considered to interfere mainly with lymphocyte trafficking to the gut, a detailed characterization of its immunological mode of action recently pointed primarily toward its influence on the innate, rather than on the adaptive immune system.[@bib11]

To identify the most suitable patients for vedolizumab therapy, we here studied colonic transcriptomic data of IBD patients initiating vedolizumab, performed pathway analysis and deconvolution, and searched for predictive markers of vedolizumab-specific endoscopic remission.

Materials and Methods {#sec1}
=====================

Patient Selection {#sec1.1}
-----------------

This prospective study was carried out at the University Hospitals Leuven (Leuven, Belgium). Independent validation cohorts were recruited in the same center as well as in the IBD unit of the Hospital Clínic (Barcelona, Spain). Endoscopy-derived inflamed colonic biopsies were obtained from consecutive IBD patients initiating biologic therapy (vedolizumab, adalimumab, or infliximab). All patients had endoscopically proven active disease, and they all had to be naïve for the drug that was initiated at inclusion. Patients received vedolizumab 300 mg at baseline and weeks 2--6, with subsequent administration every 8 weeks. All CD patients received an additional infusion at week 10. In case of anti-TNF therapy, patients received infliximab (CT-P13) 5 mg/kg at baseline and week 2--6, with subsequent administration every 8 weeks. Adalimumab was administered 160 mg subcutaneously at baseline and 80 mg subcutaneously at week 2, with 40 mg subcutaneously every other week thereafter. To reduce the risk of including treatment failures secondary to immunogenicity (and not drug mechanistic failure) or non--drug-related responders, all anti-TNF treated patients had to have a good drug exposure, defined as a maintenance trough level or \>3.0 μg/mL for infliximab and \>5.0 μg/mL for adalimumab. Due the lack of agreement on the targeted threshold for vedolizumab, if any, we did not include an exposure requirement in the definition of (non)response for vedolizumab.

All included Belgian patients had given written consent to participate in the Institutional Review Board approved IBD Biobank of University Hospitals Leuven, Belgium (B322201213950/S53684). All included Spanish patients had given written consent after approval of the study by the Ethics Committee of the University Hospital Clínic Barcelona, Spain (2012/7956).

Biopsy Collection {#sec1.2}
-----------------

All biopsies were taken at the most affected site, at the edge of the ulcerative surface. Biopsies were taken during endoscopy before the start of therapy, stored in RNALater buffer (Ambion, Austin, TX) and preserved at --80°C. RNA was subsequently extracted and sequenced (see [Supplementary Methods](#appsec1){ref-type="sec"}). Additional biopsies were immediately fixed in formalin for up to 5 hours and then dehydrated, cleared, and paraffin-embedded for histological examination and immunohistochemistry.

Endoscopic Outcomes {#sec1.3}
-------------------

Outcome was assessed objectively through ileocolonoscopy at a fixed time point. In CD patients, endoscopic remission was evaluated after 6 months, and defined as a complete absence of ulcerations, whereas in UC it was defined as a Mayo endoscopic subscore ≤1. Due to national reimbursement criteria, all UC patients were endoscopically assessed at week 8 (adalimumab) or week 14 (infliximab and vedolizumab).

Quantitative Real-Time Polymerase Chain Reaction {#sec1.4}
------------------------------------------------

Gene expression of selected markers in inflamed colonic biopsies was studied through quantitative real-time polymerase chain reaction (qPCR) analysis. Complementary DNA (cDNA) was synthesized from 0.500 μg of total RNA using the RevertAid H Minus First Strand cDNA synthesis kit (Fermentas, St. Leon-Rot, Germany). The primers for the housekeeping β-actin gene were synthesized by Sigma-Genosys (Haverhill, United Kingdom) ([Supplementary Table S1](#tblS1){ref-type="table"}) and 10-μM stock solution was used to make the reaction mixture (5-μL SybrGreen, 0.2-μM forward and reverse primer, 2-μL cDNA sample, 2.8-μLRNAse-free H~2~O). All samples were run in duplo. Samples were analyzed with the Lightcycler 480 (Roche, Basel, Switzerland). The following amplification program was used: 5 minutes 95°C, 45 × (10 seconds 95°C, 15 seconds 60°C, 15 seconds 72°C), 5 seconds 95°C, 1 minute 60°C, 4°C.

To determine the expression of all other genes (*PIWIL1*, *MAATS1*, *DCHS2*, *RGS13*), validated target-specific primers were used for TaqMan (Thermofisher Scientific, Massachusetts) qPCR ([Supplementary Table S2](#tblS2){ref-type="table"}). A total reaction volume of 20 μL was made: 10-μL TaqMan fast advanced master mix, 1-μL TaqMan assay (containing both primers and probe), 2-μL cDNA sample, 7-μL RNAse-free H~2~O. Samples were analyzed with the Applied Biosystems 7500 Fast (Applied Biosystems, Foster City, CA). The following amplification program was used: 5 minutes 95°C, 40 × (3 seconds 95°C, 30 seconds 60°C), 4°C. Samples were analyzed using the comparative (ΔΔ) Ct method with normalization to the housekeeping gene β-actin.

Immunohistochemistry {#sec1.5}
--------------------

To localize the corresponding proteins of the predictive panel in colonic mucosa, immunohistochemical stainings were performed on 5-μm-thick step slides prepared from paraffin-embedded endoscopy-derived inflamed colonic biopsies from IBD patients, taken before vedolizumab. Endogenous peroxidase activity was blocked in deparaffinated sections by incubating the slides for 20 minutes in a 0.3% solution of H~2~O~2~ in methanol. Epitope retrieval was performed by heating the slides for 30 minutes in Tris/EDTA buffer (pH 9) at 98°C. Specific protocols for each protein are summarized in [Supplementary Table S3](#tblS3){ref-type="table"}. All procedures were conducted automatically by the BOND MAX autostainer (Leica Microsystems Ltd, Heerbrugg, Switzerland). The BOND polymer refine Detection kit (Leica Microsystems Ltd) was used for visualization of bound primary antibody according to the manufacturer's instructions. An IBD-experienced pathologist (G.D.H.) evaluated all stains. Microscopic images were acquired with Leica Application Suite V4.1.0. software using a Leica DFC290 HD camera (Leica Microsystems Ltd) mounted on a Leica DM2000 light-emitting diode bright field microscope.

Statistical Analysis {#sec1.6}
--------------------

All machine learning based analyses were carried out using R version 3.5.0 (R Development Core Team, Vienna, Austria). Unlike conventional statistics, for machine learning purposes the initial vedolizumab dataset (n = 31 samples) was randomly partitioned into a training (two-thirds) and validation (one-third) set. Predictive modeling was performed using the randomGLM (RGLM) package, which shares the advantages of a random forest (excellent predictive accuracy, feature importance measures, out-of-bag estimates of accuracy) with those of a forward-selected generalized linear model (interpretability).[@bib12] Parameter choices were optimized according to the developers suggestions, with parameters *nBags* = 100, *nFeaturesInBag =* 5, *nCandidateCovariates =* 5. The identified signature was validated in several independent cohorts using ConsensusClusterPlus.[@bib13] qPCR expression results were used in binary logistic regression analysis, whereupon predicted probabilities were used to assess performance with receiver-operating characteristic analysis. A false discovery rate (FDR) correction was applied during differential gene expression and pathway analysis, to correct for multiple testing. A 2-tailed FDR-corrected *P* value \<.25 was considered significant. For all other analysis, a 2-tailed nominal *P* value \<.05 was considered significant.

Results {#sec2}
=======

Patient Characteristics {#sec2.1}
-----------------------

Thirty-one patients with endoscopically active colonic inflammatory bowel disease (11 CD, 20 UC) with a median disease duration of 8.4 (interquartile range, 4.0--15.3) years were included before their first vedolizumab administration ([Table 1](#tbl1){ref-type="table"}). One-third (n = 10, 32.3%) received vedolizumab as first-line biological therapy. In UC, an endoscopic remission rate of 65.0% was observed after 14 weeks, whereas 54.5% of CD patients achieved endoscopic remission after 6 months. Endoscopic remitters and nonremitters did not significantly differ in baseline characteristics (*P* \> .05). Baseline features of the validation cohorts are also reported in [Table 1](#tbl1){ref-type="table"}.Table 1Clinical Characteristics of the Inception Cohort, Validation Cohort 2, and Validation Cohort 4Inception cohort discovery + validation 1 (n = 31)Validation cohort 2 RNA sequencing (n = 16)Validation cohort 4 qPCR (n = 37)Diagnosis Ulcerative colitis20 (64.5)7 (43.8)30 (81.1) Crohn's disease11 (35.5)9 (56.3)7 (18.9)Women17 (54.8)7 (43.8)25 (67.6)Age, *y*45.3 (29.6--56.3)44.2 (26.0--55.8)38.2 (31.0--48.0)Disease duration, *y*8.4 (4.0--15.3)3.7 (1.6--20.7)6.9 (1.7--11.7)Disease location[a](#tbl1fna){ref-type="table-fn"} L10 (0)0 (0)0 (0) L22 (18.2)4 (44.4)3 (42.9) L39 (81.8)5 (56.6)4 (57.1) L4 modifier2 (18.2)2 (22.2)0 (0) E13 (15.0)1 (14.3)8 (26.7) E210 (50.0)2 (28.6)9 (30.0) E37 (35.0)4 (57.1)13 (43.3)Disease behavior[a](#tbl1fna){ref-type="table-fn"} B16 (54.5)4 (44.4)6 (85.7) B23 (27.3)2 (22.2)0 (0.0) B32 (18.2)3 (33.3)1 (14.3) Perianal involvement5 (45.5)2 (22.2)2 (28.6)Steroid use during induction Topical10 (32.3)5 (31.3)15 (40.1) Systemic8 (25.8)6 (37.5)7 (16.2)Previous anti-TNF exposure Naïve10 (32.3)4 (25.0)26 (70.3) Exposed21 (67.7)12 (75.0)13 (29.7) C-reactive protein, *mg/L*2.0 (0.9--6.7)3.8 (1.4--7.2)1.8 (0.7--6.0)Endoscopic remission Yes19 (61.3)5 (31.1)14 (37.8) No12 (38.7)11 (68.9)23 (62.2)[^1][^2][^3]

Additionally, colonic biopsies from 20 actively inflamed patients (6 CD, 14 UC) initiating anti-TNF therapy, of whom 17 (90.0%) were entirely anti-TNF naïve, were collected. None of them had been exposed to vedolizumab before ([Supplementary Table S4](#tblS4){ref-type="table"}).

Differential Gene Expression and Deconvolution {#sec2.2}
----------------------------------------------

Within the inflamed colonic biopsies before vedolizumab, 186 genes were differentially expressed between remitters and nonremitters at a nominal *P* \< .005 level ([Supplementary Table S5](#tblS5){ref-type="table"}). Among them, only 44 genes remained significantly different after applying a conservative 0.25-FDR threshold of significance. However, just 5 reached the stringent 0.05-FDR cutoff threshold of significance: *KRT23*, *TMEM35*, *DCHS2*, *CLDN8*, and *IFI6* ([Figure 1](#fig1){ref-type="fig"}). None of them was differentially expressed between CD and UC samples (*P* \> .05). Genes previously linked to anti-TNF nonresponsiveness, were not differentially expressed between vedolizumab responders and nonresponders: *OSM* (*P =* .76), *IL13RA2* (*P =* .54), and *TREM1* (*P =* .46). Similarly, no significant differential expression was observed in *MAdCAM-1* (*P =* .59), integrin α4 subunit *ITGA4* (*P =* .97), or integrin β7 subunit *ITGB7* (*P =* .99).Figure 1Top 5 differentially expressed genes. Visual representation of the top differentially expressed genes in mucosal biopsies of patients responding and not responding to vedolizumab. FDR, false discovery rate--corrected *P* value; logFC, log fold change. Top 5 differentially expressed genes: (*A*) KRT23, (*B*) TMEM35, (*C*) DCHS2, (*D*) CLDN8, and (*E*) IFI6.

Pathway analysis on the 186 differentially expressed genes using ingenuity pathway analysis revealed rather unspecific top canonical pathways (granulocyte adhesion and diapedesis \[*P* = 9.4 × 10^--5^\] and role of cytokines in mediating communication between immune cells \[*P* = 1.1 × 10^--3^\]). Similarly, a more focused gene enrichment analysis using gene set enrichment analysis, looking at Gene Ontology (GO) gene sets covering leukocyte migration and cell adhesion confirmed the GO leukocyte migration gene set, among many other trafficking and adhesion gene sets, indeed significantly enriched in nonremitters (*P =* .006) ([Supplementary Table S6](#tblS6){ref-type="table"}, [Supplementary Figure S1](#figS1){ref-type="fig"}). Predicted upstream regulators in vedolizumab nonremitters included TNF (*P* = 2.2 × 10^--10^), nuclear factor kappa B (*P* = 4.6 × 10^--9^), and interleukin 1β (*P* = 1.8 × 10^--8^). Deconvolution methods showed a significant enrichment of effector memory CD4^+^T cells (*P =* .008), monocytes (*P =* .005), M1 macrophages (*P =* .05), and regulatory T cells (*P =* .05) in nonremitters before vedolizumab initiation. In contrast, naïve B cells were significantly enriched in colonic biopsies of remitters (*P =* .03) ([Figure 2](#fig2){ref-type="fig"}).Figure 2Cellular deconvolution. Visual representation of the enrichment scores for the individual cells types identified being differentially represented between vedolizumab (*A*) nonremitters and (*B*) remitters, according to deconvolution techniques on the baseline transcriptome.[@bib31] T regs, regulatory T cells; T em, effector memory cells.

A 4-Gene Based Model Predicting Endoscopic Outcome to Vedolizumab Therapy {#sec2.3}
-------------------------------------------------------------------------

The initial dataset containing 31 inflamed colonic IBD biopsies, was randomly split into discovery (n = 20) and validation (n = 11) sets. Within the dataset of all 44 differentially expressed genes (at the 0.25-FDR level), we identified a 4-gene signature predicting endoscopic remission to vedolizumab using randomized general linear regression. A model containing *RGS13*, *DCHS2*, *MAATS1*, and *PIWIL1* expression could accurately (accuracy 80.0%) predict endoscopic remission in the discovery cohort. Similarly, the same model could accurately differentiate vedolizumab remitters from nonremitters in validation cohort 1 (3 nonremitters, 8 remitters) ([Table 2](#tbl2){ref-type="table"}). Importantly, *RGS13*, *DCHS2, MAATS1*, and *PIWIL1* expression was not significantly different between anti-TNF naïve and anti-TNF--exposed patients (*P*s *=* .96, .96, .99, and .98, respectively) ([Supplementary Table S7](#tblS7){ref-type="table"}).Table 2Accuracy of the 4-Gene Signature in Vedolizumab and Anti-TNF--Treated PatientsDiscovery dataset RNA-seq (n = 20; 9 NR, 11 R)Validation dataset 1 RNA-seq (n = 11; 3 NR, 8 R)Validation dataset 2 RNA-seq (n = 16; 11 NR, 5 R)Validation dataset 3 Microarray (n = 13; 9 NR, 4 R)Anti-TNF dataset RNA-seq (n = 20; NR 12, R 8)Accuracy, %80.0100.081.376.955.0Sensitivity, %81.8100.066.7100.075.0Specificity, %77.8100.090.070.041.7Positive predictive value, %81.8100.080.050.046.2Negative predictive value, %77.8100.081.8100.071.4Positive likelihood ratio3.7∞6.673.31.3Negative likelihood ratio0.200.300.6[^4]

Subsequently, we recruited another 16 consecutive patients initiating vedolizumab (validation cohort 2) ([Table 1](#tbl1){ref-type="table"}), in whom we could accurately predict remission (accuracy 81.3%) through unsupervised consensus clustering based on the expression of the 4 identified genes ([Table 2](#tbl2){ref-type="table"}). Combining validation cohort 1 and 2 together (14 nonresponders, 13 responders) ultimately resulted in an 88.9% accuracy (positive likelihood ratio \[LR+\] 11.1 and negative likelihood ratio \[LR--\] 0.15). All 4 genes were significantly upregulated in remitters, with *PIWIL1* not at all expressed in any of the nonremitters ([Supplementary Figure S2](#figS2){ref-type="fig"}). In contrast, the 4-gene signature was not accurate to predict response in inflamed ileal biopsies (accuracy 50.0%). Furthermore, the expression of these genes did not correlate with mucosal *TNF/IL6* or C-reactive protein, suggesting that they do simply not reflect the inflammatory burden.

Validation of the 4-Gene Model in a Publicly Available Dataset From the GEMINI Long-Term Extension Program {#sec2.4}
----------------------------------------------------------------------------------------------------------

Publicly available transcriptomic data in vedolizumab treated patients are limited.[@bib14] Therefore, we could validate our signature only in a small independent cohort of 13 UC patients (validation cohort 3), treated during the GEMINI long-term extension program (GSE73661). Those patients received vedolizumab according to the standard dosing (weeks 0, 2, and 6), and were endoscopically assessed at week 14. In this historic cohort, the 4-gene panel could accurately identify those patients who would not benefit from vedolizumab therapy (LR-- 0.0, overall accuracy 76.9%) ([Table 2](#tbl2){ref-type="table"}).

The combination of validation cohorts 1, 2, and 3 did confirm a predictive accuracy \>80.0% in both CD and UC patients separately.

Validation of the 4-Gene Model in an Independent Cohort Using qPCR {#sec2.5}
------------------------------------------------------------------

This 4-gene panel was tested in an additional Belgian-Spanish cohort using qPCR (30 UC, 7 CD) ([Table 1](#tbl1){ref-type="table"}), accurately differentiating remitters from nonremitters with an area under the curve (AUC) of 78.6% (95% confidence interval, 63.8--93.3%; *P =* .003) ([Figure 3](#fig3){ref-type="fig"}). In contrast, the predictive accuracy of the individual genes was clearly lower: *PIWIL1* AUC 69.6% (*P =* .05), *MAATS1* AUC 61.2% (*P =* .20), *RGS13* AUC 49.0% (*P =* .69), and *DCHS2* AUC 50.4% (*P =* .80).Figure 3Receiver-operating characteristic statistics predicting vedolizumab-induced endoscopic remission based on the colonic 4-gene predictive panel in an independent Belgian-Spanish validation cohort. AUC, area under the curve.

A Vedolizumab-Specific Signature {#sec2.6}
--------------------------------

To confirm the vedolizumab specificity of this panel, its predictive accuracy was tested in a cohort of 20 patients initiating anti-TNF therapy. In contrast to vedolizumab, this signature could not predict endoscopic outcome in anti-TNF--treated patients (accuracy 55.0%, LR+ 1.3, LR-- 0.6) ([Table 2](#tbl2){ref-type="table"}).

Immunohistochemistry {#sec2.7}
--------------------

*PIWIL1* expression could not at all be observed in regenerating epithelium ([Supplementary Figure S3](#figS3){ref-type="fig"}), whereas it was clearly expressed in goblet cells and to some extent in stromal cells in inflamed tissue ([Figure 4](#fig4){ref-type="fig"}*A*). In contrast, *MAATS1* was predominantly identified in endothelial cells and only weakly in epithelium and smooth muscle cells ([Figure 4](#fig4){ref-type="fig"}*B*). Likewise, *DCHS2* was found in endothelial cells ([Figure 4](#fig4){ref-type="fig"}*C*). Finally, *RGS13* was expressed solely in the epithelial barrier, cytoplasmic just above the cell nucleus ([Figure 4](#fig4){ref-type="fig"}*D*).Figure 4(*A*) Immunohistochemical *PIWIL1* staining in inflamed inflammatory bowel disease (IBD) colon (original magnification \[OM\] ×100). (*B*) Immunohistochemical *MAATS1* staining in inflamed IBD colon (OM ×100). (*C*) Immunohistochemical *DCHS2* staining in inflamed IBD colon (OM ×200). (*D*) Immunohistochemical *RGS13* staining in inflamed IBD colon (OM ×200).

Discussion {#sec3}
==========

Despite the therapeutic success of emerging drugs in IBD,[@bib1]^,^[@bib2] endoscopic remission rates are still not exceeding 30%. Besides a better patient selection and individualized dosing schemes using population pharmacokinetic-pharmacodynamic modeling,[@bib15] therapy outcomes could be further improved using predictive biomarkers. In this study, we identified and validated a 4-gene colonic expression panel predicting endoscopic success of vedolizumab therapy specifically.

Very little is known about the role of the 4 identified genes, *PIWIL1*, *MAATS1*, *RGS13*, and *DCHS2* in IBD, and even in normal colonic mucosa to a larger extent. Based on our results, they do not reflect the mucosal inflammatory burden. *Piwi-like protein 1* (*PIWIL1*) encodes a member of the PIWI subfamily of Argonaute proteins.[@bib16] PIWI proteins and PIWI-interacting RNAs participate in many vital biological processes, including cell proliferation, migration, survival, and inflammation.[@bib17]^,^[@bib18] Hence, their involvement in wound healing and tissue regeneration does not come as a surprise.[@bib17] Although its highest expression is observed in germline tissue, *PIWIL1* has been reported along the gastrointestinal tract.[@bib19] Existing studies mainly focused on the aberrant expression of *PIWIL1* in tumors,[@bib18] but the biological role of *PIWIL1* in IBD has never been elucidated. As *PIWIL1* is upregulated in vedolizumab remitters, it may suggest that those patients have an a priori higher likelihood of stem cell renewal/survival, as compared with nonresponders. PIWIL1 immunohistochemistry on the other hand pointed toward the contribution of goblet cells, which are fully differentiated and hence not expected to represent a more proliferative state. Whether PIWIL1 affects goblet cell function is currently unknown, and how this is linked to vedolizumab efficacy in particular cannot be answered based on the current study.

In contrast, *MAATS1* (or *C3orf15*) and *DCHS2* (or *Cadherin J*) were mainly found on endothelial cells, which could suggest that both may interfere with diapedesis and cell migration, key processes in the mode of action of vedolizumab. Overall, *MAATS1* is predominantly expressed in the fallopian tube and testis, but expression along the gastrointestinal tract has been reported.[@bib19] However, *MAATS1* function is entirely unknown so far. In contrast, *DCHS2* is implicated in cell adhesion, considered an unconventional cadherin, and mainly expressed in the reproductive system, the gastrointestinal tract and the brain.[@bib19]^,^[@bib20]

Finally, *RGS13* was mainly observed in our staining in the epithelial barrier. Apart from its abundant expression in innate and adaptive immune cells, it is indeed expressed throughout the digestive system.[@bib19] Interestingly, *RGS13* expression impacts CD4^+^ T cell migration through the RGS13-induced unresponsiveness to CXCL12, despite high levels of its receptor CXCR4 on T cells.[@bib21] As CXCL12 and CXCR4 are upregulated and constitutively expressed by intraepithelial cells (IECs) in patients with active IBD, a positive feedback loop has been suggested: increased expression and secretion of CXCL12 by IECs result in an accumulation of CXCR4^+^ monocytes and T cells,[@bib22]^,^[@bib23] which on their turn contribute to additional CXCL12 expression by IECs.[@bib22] But, increased *RGS13* expression results in impaired *CXCL12* responsiveness, implying less leukocyte trafficking. Additionally, CXCL12 itself improves the adhesion of α4β7^+^ cells to MadCAM-1 by increasing the α4β7 affinity, without affecting the subcellular distribution of α4β7.[@bib24] Whether this also affects vedolizumab efficacy remains unknown.

The reduced a priori leukocyte trafficking in vedolizumab endoscopic remitters, for instance also reflected by an increased *RGS13* expression in the 4-gene model, was also observed in our unsupervised transcriptome-wide analysis. This raises the question whether many more escape mechanisms exist to maintain leukocyte trafficking and subsequent intestinal inflammation in nonremitters, regardless of α4β7 blocking. Using deconvolution techniques, we identified an enrichment of proinflammatory M1 macrophages (M1ϕ) in nonresponders, before vedolizumab. In contrast to nonclassical monocytes essential for intestinal wound healing mediated by M2ϕ (which are blocked by vedolizumab therapy),[@bib25] classical monocytes can still migrate via the αLβ2-ICAM1 pathway, differentiate in proinflammatory M1ϕ and maintain intestinal inflammation.[@bib26] Vedolizumab may also affect the innate immune system, as described by Zeissig et al.[@bib11] They demonstrated a switch from an M1ϕ to a M2ϕ environment, but only in vedolizumab clinical responders. Our data now demonstrate that endoscopic nonremitters have an a priori abundance of M1ϕ already, together with an increased proportion of monocytes and effector memory CD4^+^T cells as compared with remitters. As vedolizumab is not able to reduce the abundance of effector memory CD4^+^T cells,[@bib11] the additional abundance of regulatory T cells in nonresponders is not able to dampen the proinflammatory environment, despite vedolizumab therapy.

Finally, we observed a significant baseline enrichment of naïve B cells in vedolizumab endoscopic remitters. The data by Zeissig et al[@bib11] also pointed toward the B cell compartment, as B cell receptor signaling was significant downregulated upon vedolizumab exposure. However, the role of the complex B cell biology in IBD pathogenesis is very poorly understood,[@bib27] and mainly disregarded after the failure of the anti-CD20 rituximab in randomized trial in UC,[@bib28] which obviously acts differently than vedolizumab. Why we observe a significant enrichment of naïve B cells in vedolizumab endoscopic remitters cannot be fully answered based on our findings, and raises the question whether a vedolizumab induced depletion of this cell population is key to its therapeutic success. Indeed, recent data on a small cohort of HIV-infected IBD patients demonstrated that vedolizumab therapy importantly reduced naïve B cells in intestinal mucosa,[@bib29] preventing subsequent priming by dendritic cells, who are surveying the mucosal barrier for invading pathogens.

Although we demonstrated the vedolizumab specificity of this 4-gene panel as compared with anti-TNF treated patients, the predictive accuracy in ustekinumab- or tofacitinib-treated patients is currently unknown. Furthermore, the rather limited sample size in this pilot project warrants caution. However, the validation in several independent, heterogeneous datasets suggests its true clinical and biological relevance. Finally, the enrichment scores derived through xCell deconvolution techniques raise novel hypotheses, but the need further microscopic or flow cytometric validation as the enrichment scores cannot be interpreted as proportions.

In conclusion, we identified and validated a 4-gene vedolizumab specific signature predicting therapeutic success in IBD, highlighting novel pathways previously unrecognized in vedolizumab efficacy. Additionally, our transcriptome wide unbiased analysis of inflamed colonic biopsies before vedolizumab therapy suggested an a priori increased leukocyte trafficking in endoscopic nonremitters, and provided novel insights in the vedolizumab mode of action, including the involvement of B cell compartment in vedolizumab response.

Supplementary Methods {#appsec1}
=====================

Isolation of RNA {#appsec1.1}
----------------

Total RNA from inflamed biopsies was extracted using the AllPrep DNA/RNA Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions, after tissue lysis using the FastPrep Lysing Matrix D tubes (MP Biomedicals, Brussels, Belgium) with RLT lysis buffer (Qiagen, Hilden, Germany). For the Barcelona validation cohort, RNA was extracted using the RNEasy Mini Kit (Qiagen, Hilden, Germany). The integrity and quantity of all RNA was assessed with a 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA). Extracted RNA was stored at --80°C until further processing.

RNA Sequencing {#appsec1.2}
--------------

Next-generation 50 base pair single-end sequencing was performed using the Illumina HiSeq 4000NGS, after library preparation using the TruSeq Stranded messenger RNA protocol (Illumina, San Diego, CA) according to the manufacturer's instructions. Raw RNA-sequencing data were aligned to the reference genome using Hisat2 version 2.1.0, absolute counts generated using HTSeq, where after counts were normalized, protein-coding genes selected according the Ensemble hg 19 reference build, and differential gene expression assessed using the DESeq2 package. RNA-sequencing data have been deposited in the ArrayExpress database at EMBL-EBI ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress){#intref0010}) under accession number E-MTAB-7845. Pathway analysis was performed using the Gene Set Enrichment Analysis software (Broad Institute, Massachusetts Institute of Technology, and Regents of the University of California),[@bib33] and Ingenuity Pathway Analysis (Aarhus, Denmark). Cell deconvolution was performed using the xCell online tool, which harmonized 1822 pure human cell type transcriptomes allowing the distinction of 64 immune and stromal cell types.[@bib34]
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Transcript Profiling {#appsec4}
====================

RNA-sequencing data have been deposited in the ArrayExpress database at EMBL-EBI ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress){#intref0015}) under accession number E-MTAB-7845.Supplementary Figure S1Gene set enrichment analysis enrichment of the Gene Ontology (GO) leukocyte migration gene set in the colonic transcriptomic dataset. The bar-code plot indicates the position of the genes on the expression data rank, sorted by its association with vedolizumab-induced endoscopic remission (*P \<* .001).Supplementary Figure S2Differential expression of the 4 genes in the predictive panel. Visual representation of the differential gene expression in mucosal biopsies of patients responding and not responding to vedolizumab therapy of the 4 genes included in the predictive panel. FDR *P* value, false discovery rate corrected *P* value; logFC, log fold change. Differential expression of the 4 genes in the predictive panel: (*A*) PIWIL1, (*B*) MAATS1, (*C*) RGS13, and (*D*) DCHS2.Supplementary Figure S3Immunohistochemical *PIWIL1* staining in regenerating colonic epithelium (original magnification ×50).Supplementary Table S1Details of the Forward and Reverse Primers Used for the Beta Actin qPCR Analysis, Including the amplicon Length, Melt Temperature, 5′-3′ Sequence, and NCBI Accession NumberPrimerAmplicon lengthTemperature (°C)Sequence (5′-3′)GeneAccession numberReferenceForward10859.9ACAATGTGGCCGAGGACTTT*Beta actin*NM_001101.3Own design primer BLAST[@bib35]Reverse59.7TGGGGTGGCTTTTAGGATGG[^5]Supplementary Table S2Details of Target-Specific TaqMan PrimersGeneTarget-specific primerCompany*PIWIL1*Hs01041737_m1Thermo Fisher Scientific*MAATS1*Hs00398573_m1Thermo Fisher Scientific*DCHS2*Hs03006670_m1Thermo Fisher Scientific*RGS13*Hs00243182_m1Thermo Fisher ScientificSupplementary Table S3Overview Primary Antibodies ImmunohistochemistryProteinDilution primary antibodyPrimary AbIncubation details primary AbPIWIL11:2000Rabbit polyclonal anti-PIWIL1 Ab -- HPA018798 (Sigma-Aldrich)30 min at RTMAATS11:800Mouse monoclonal anti-MAATS1/C3orf15 Ab -- MA5-26540 (Invitrogen)30 min at RTDCHS21:400Rabbit polyclonal anti-DCHS2 Ab -- HPA064159 (Sigma-Aldrich)30 min at RTRGS131:200Rabbit polyclonal anti-RGS13 Ab -- HPA044952 (Sigma-Aldrich)30 min at RT[^6]Supplementary Table S4Clinical Features of the Anti-TNF--Treated CohortDiagnosis Ulcerative colitis12 (60.0) Crohn's disease8 (40.0)Therapy Adalimumab12 (60.0) Infliximab8 (40.0)Women12 (60.0)Age, *y*33.7 (21.6--48.0)Disease duration, *y*1.4 (0.2--4.8)Disease location[a](#tblS4fna){ref-type="table-fn"} L10 (0.0) L21 (16.7) L35 (83.3) L4 modifier1 (16.7) E10 (0.0) E211 (83.3) E33 (21.4)Disease behavior[a](#tblS4fna){ref-type="table-fn"} B13 (50.0) B23 (50.0) B30 (0.0) Perianal involvement1 (16.7)Steroid use during induction Topical3 (15.0) Systemic7 (35.0)Immunomodulators during induction1 (5.0)C-reactive protein, *mg/L*5.1 (1.4--14.2)Endoscopic remission Yes8 (40.0) No12 (60.0)[^7][^8][^9]Supplementary Table S5All Differentially Expressed Genes at the Nominal Significance *P* \< .005 LevelGeneBase meanlog2FoldChangeNominal *P* valueFDR-Adjusted *P* value*KRT23*16.7180859--2.02420521.09 × 10^--8^.000168888*TMEM35*22.00731441.023871915.24 × 10^--7^.004044778*DCHS2*14.21680321.568224722.75 × 10^--6^.014128976*CLDN8*90.06084224.396104384.96 × 10^--6^.019127255*IFI6*334.629287--0.74725996.36 × 10^--6^.019615927*APOBEC3A*70.4624261--1.68135822.93 × 10^--5^.075378873*PCOLCE2*7.461678682.224767483.85 × 10^--5^.084915322*CXCL6*367.065443--1.86014955.42 × 10^--5^.096168704*P2RX2*3.988036792.337362095.61 × 10^--5^.096168704*HEPHL1*7.19784773--2.71206336.93 × 10^--5^.106875332*GZMB*179.696681--1.235948.000105257.126064653*CCL3*110.886222--1.370798.000106858.126064653*DCBLD1*335.800147--0.4339657.000109094.126064653*IL18RAP*88.2525652--0.9455257.000114389.126064653*IL32*1239.13865--0.516138.000191042.196506067*RGS13*26.7137781.00558131.000209322.196608037*C16orf89*27.46766450.79870715.000216627.196608037*RASGRP4*66.4823444--0.8669479.000229439.196667853*GLRA2*12.88014462.03544389.000259165.207049407*NCF2*451.245388--0.8127664.000276283.207049407*PPP1R3C*50.46721130.77759178.000281809.207049407*PTGER1*5.95195593--1.8184337.000319712.209795607*AFF3*85.79594970.72082547.000327476.209795607*SERPINA9*5.578816373.07311416.000328424.209795607*ITPRIPL2*719.964066--0.3225183.000339937.209795607*SHC1*1492.18376--0.2762233.000370729.212595281*MAATS1*16.84982691.35939925.000393874.212595281*PRF1*175.562754--0.7783421.000408969.212595281*RIPK2*223.222424--0.4889622.000415642.212595281*C7*206.9021411.13251488.000431099.212595281*VASN*134.723245--0.9239671.000469609.212595281*LILRB2*378.028889--1.0345434.00050092.212595281*OCA2*5.774093231.79797243.00050103.212595281*GDF6*5.727696331.73964914.000509621.212595281*HMG20A*436.3906390.2244065.000515674.212595281*ARRB2*608.61371--0.4538602.000518642.212595281*MMP1*3428.22966--2.0023607.000527115.212595281*IFNG*39.9970933--1.7218582.00053709.212595281*C21orf88*75.04395772.48943313.000537379.212595281*CEBPB*427.693647--0.8978266.000657776.24482901*CSF2*22.9106571--1.7392829.000659524.24482901*ZNF587B*108.099950.32214911.000668663.24482901*PIWIL1*1.671388533.85503952.000682457.24482901*EVA1B*59.2723597--0.9274526.000698197.24482901*SLC13A2*65.21677721.48745286.000751791.254142023*HSD11B1*70.3742699--1.0479977.000783544.254142023*SHISA3*12.42272351.4228452.000796262.254142023*NTRK3*10.77519021.20335112.00079719.254142023*S100A3*32.1489835--1.1512714.000810185.254142023*NPTX2*112.143113--1.7394179.000823586.254142023*CMIP*1060.93813--0.2499559.000847772.256475996*WBSCR27*13.62748881.30468994.000930061.275959815*APOL1*3402.48609--0.8000499.000968958.282076494*LILRA5*142.345939--1.2109718.001013086.289461169*TENM2*4.012797652.20373098.001039446.29159288*TBC1D1*837.906313--0.2292631.00112296.299758073*KCNH2*74.39915270.64204441.001154201.299758073*HSPA12B*77.7690355--0.7681986.001154923.299758073*PFKFB4*177.110178--0.634147.001188816.299758073*SOX18*75.6968692--1.0378603.001217785.299758073*FCGR2A*590.678255--1.0078412.001242733.299758073*OSCAR*51.8112129--0.6944374.00124279.299758073*RP11-812E19.9*21.3315831--1.08004.001243239.299758073*MMP3*4282.89856--1.863898.001298899.299758073*ADNP2*329.9183770.19372723.001305613.299758073*PDPN*555.884207--0.9337707.001322834.299758073*PTAFR*604.274834--0.6096574.001323439.299758073*PLAU*1885.1355--1.0021618.001329836.299758073*MMP14*2445.67364--0.5253513.001344761.299758073*HCAR2*118.63972--1.6680141.001360294.299758073*FFAR2*158.960936--1.2633905.001379404.299758073*SLC43A2*499.956189--0.4968154.001422941.301417508*GNAI1*286.287253--0.3617917.001436971.301417508*GBP5*1201.6973--1.0456035.001458182.301417508*KRTAP13-2*7.313850494.80719515.001478671.301417508*ZNF525*93.38275610.44302787.001579396.301417508*CLGN*10.73315271.03788853.001585583.301417508*WARS*7144.39929--0.8301275.001626954.301417508*PXDN*1131.81879--0.6205878.001628192.301417508*NRCAM*80.9563399--1.1639303.001639771.301417508*TBX2*211.98147--0.5767591.00165562.301417508*CCR1*328.757107--0.7665532.001700304.301417508*GPRASP1*96.65151050.43756646.001703022.301417508*TIMM10*242.7560120.41371367.001710192.301417508*FCN3*84.2750831--1.407743.001752829.301417508*DRAXIN*3.8240981--1.4868304.001762212.301417508*RAB31*1034.09613--0.5151868.001763017.301417508*IL7R*1452.38809--0.626916.001778229.301417508*FAM26F*223.730022--0.9277878.00179398.301417508*CA1*2884.818512.07665726.001794694.301417508*PRELP*149.2603821.06887891.001826146.301417508*RGS3*603.119819--0.313215.001894436.301417508*GSDMC*13.6827704--1.3250678.001897953.301417508*TYMP*1464.76898--0.6961674.001937775.301417508*MYO1F*606.425133--0.5323932.001947213.301417508*EDN1*151.13679--0.4851836.00195317.301417508*MT2A*754.065--0.8008857.001957318.301417508*CD300C*38.6480185--0.6878881.001965729.301417508*CNTN1*34.82071641.20250742.001979141.301417508*SLC9A9*151.5146290.39011774.00198252.301417508*APOL2*1380.80307--0.618163.001991339.301417508*GLT1D1*30.5540448--1.3354594.001992649.301417508*KIAA2022*8.395459591.11065981.002032918.303055283*KANK4*11.99966941.24284523.002050125.303055283*EMR2*368.717865--0.8265429.002062402.303055283*CHMP4C*264.8618810.5013719.00211717.307508524*CXXC4*27.21227690.52250071.002132569.307508524*PDGFB*178.670281--0.6208979.002153947.307715287*PRKCDBP*113.367496--0.7947516.002195238.310736989*HCAR3*166.644571--1.7971432.002252748.312805681*MEFV*69.9932486--1.0795521.002255787.312805681*ITIH1*3.765114851.80120388.002270674.312805681*ZNF180*96.81099380.28440763.00232086.31688978*ACSL1*769.356769--0.6292047.002375655.321526177*SERPINH1*1448.64285--0.4357825.002401686.322222743*KCNJ15*74.2169719--1.3884412.00247467.329152443*FPR2*152.266592--1.5619318.002610446.343491034*PML*856.765038--0.4504262.002626997.343491034*CRIP3*9.858462531.13141354.002653799.344079565*PAK3*14.29951180.87116381.002741388.352095927*S100A8*516.102614--1.4489693.002761268.352095927*AGTRAP*303.595404--0.3661557.002851262.357943211*NRBF2*254.204633--0.2179738.00285909.357943211*LCN8*2.661740824.5263242.002886973.357943211*LCP2*700.802206--0.5292133.002903855.357943211*CD97*1624.92009--0.2937652.002923122.357943211*RNF149*966.868431--0.3855569.003016884.359954883*FAM20C*554.457254--0.7291105.003027376.359954883*IL6*137.460364--1.8728125.003039422.359954883*MAMDC2*77.14364181.077587.00304496.359954883*FRMD5*42.4566262--0.5517891.003056199.359954883*PRSS23*1269.57438--0.518664.003105654.36300863*ADAMTS2*404.668272--0.8236445.003170801.363452743*CXCR2*198.069766--1.5049112.003175255.363452743*CGNL1*107.067440.55456682.003210693.363452743*SLC26A7*7.979381161.15536571.003215226.363452743*MAPK4*8.790190651.59986179.003274881.363452743*GPR68*145.288283--0.6319797.003320694.363452743*CCDC85B*70.387112--1.0722359.003334462.363452743*TFB2M*208.4541530.30508172.003341185.363452743*FPR3*538.077495--0.4912119.003355985.363452743*IL10*27.9763111--0.748586.00336366.363452743*GZMH*45.6742582--0.9784585.003368575.363452743*TWIST1*22.0625386--1.1686077.003429279.367432956*KYNU*313.530786--0.8871439.003465275.368729158*P2RY6*118.969069--0.6825427.003508725.370795351*DUOXA1*41.78447291.16498649.003605027.375315993*THNSL1*71.40192980.48108439.003614439.375315993*GAS1*52.0746488--1.3020567.003624479.375315993*AJAP1*22.6129557--0.9033464.003684437.376071973*TARBP1*393.0235240.27379753.003688553.376071973*ECEL1*6.27832952--1.744911.003711289.376071973*TRPM5*25.1258890.86827164.003729277.376071973*TAP1*4573.54696--0.4324256.003804006.381116896*XIRP1*5.95863417--1.9154595.003852525.381611932*SPON2*436.782172--0.6820999.003868974.381611932*RND3*742.304639--0.3040314.003883147.381611932*PI15*236.012309--1.6421623.003944315.383224026*GBP1*2082.25661--0.688434.003961081.383224026*CDC25B*1152.1294--0.4573937.003974065.383224026*COL19A1*14.09999841.16153197.004058959.383658079*UCN2*15.8223209--1.7066439.004067746.383658079*KIAA1199*892.903884--1.4640356.004114575.383658079*FAM65C*246.664958--0.805228.004122964.383658079*TNFAIP6*103.975943--1.2385583.004124454.383658079*SPI1*442.202474--0.6064343.004127762.383658079*IL22*12.1184065--1.5552835.004226837.39051419*LOX*233.733809--0.500771.00427652.392752577*CLEC4E*72.0366822--1.0876011.004314872.392778101*HSD3B2*9.889031222.61567965.004327713.392778101*HAL*17.0775854--1.1779315.004384927.395643489*GAPT*86.19781480.5772995.004463871.396779869*SNAP29*538.224499--0.2050471.004487674.396779869*SEC22A*156.8551610.21470733.004515121.396779869*SPHK1*149.208726--0.8540513.004534048.396779869*FCGR3A*666.452688--0.8194133.004563509.396779869*CENPF*452.4253660.36369156.004563724.396779869*KLF10*769.779455--0.3019486.004608633.396779869*TWIST2*6.12323293--1.2439755.004640758.396779869*CYP27C1*11.76547840.87578612.004652416.396779869*TMEM132A*295.03094--0.7747564.004654686.396779869*CEBPD*375.693399--0.8544119.004682067.396920927*TNFAIP3*1311.60335--0.5350924.004740862.398333069*TMEM255A*37.62852250.84079489.004750359.398333069*FHL1*1126.475820.52699071.004880715.407051615*MNDA*354.070638--0.9214579.004912218.40747638Supplementary Table S6Gene Set Enrichment Analysis Results Focused on the Leukocyte Migration and Cell Adhesion Gene Ontology Gene Sets, Derived From the MSigDBGO gene setNominal *P* valueFDR corrected *P* valueLeukocyte migration.006.017Leukocyte adhesion to vascular endothelial cells.032.090Cellular extravasation.038.060Leukocyte cell adhesion.089.098Integrin-mediated signaling pathway.117.145Integrin binding.171.166Cell adhesion molecule binding.201.221Cell substrate adhesion.232.208[^10][^11]Supplementary Table S7Differential Gene Expression Between anti-TNF--Naïve and Anti-TNF--Exposed Vedolizumab PatientsGeneNominal *P* valueFDR-Corrected *P* valueLog2 fold change*RGS13*.13.960.32*DCHS2*.13.960.40*MAATS1*.62.990.22*PIWIL1*.18.981.77[^12]

These data have been presented as an oral presentation at the 14th European Crohn's and Colitis Organization Congress 2019 (Copenhagen, Denmark), 50th Digestive Disease Week 2019 (San Diego, CA), and 31st Belgian Week of Gastroenterology (Antwerp, Belgium). The authors were awarded with the Y-ECCO Congress abstract award during the 14th European Crohn's and Colitis Organization Congress 2019 (Copenhagen, Denmark).
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[^1]: Values are n (%) or median (interquartile range).

[^2]: qPCR, quantitative real-time polymerase chain reaction; TNF, tumor necrosis factor.

[^3]: Montreal classification.[@bib30]

[^4]: NR, nonresponder; R, responder; RNA-seq, RNA sequencing; TNF, tumor necrosis factor.

[^5]: qPCR, quantitative real-time polymerase chain reaction.

[^6]: Ab, antibody; RT, room temperature

[^7]: Values are n (%) or median (interquartile range).

[^8]: TNF, tumor necrosis factor.

[^9]: Montreal classification.[@bib36]

[^10]: All gene sets are enriched in the nonresponder group.

[^11]: FDR, false discovery rate; GO, Gene Ontology; TNF, tumor necrosis factor.

[^12]: FDR, false discovery rate; TNF, tumor necrosis factor.
